GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » LT-Debt-to-Total-Asset

Albert Labs International (XCNQ:ABRT) LT-Debt-to-Total-Asset : 0.15 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Albert Labs International's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.15.

Albert Labs International's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.15). It may suggest that Albert Labs International is progressively becoming more dependent on debt to grow their business.


Albert Labs International LT-Debt-to-Total-Asset Historical Data

The historical data trend for Albert Labs International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International LT-Debt-to-Total-Asset Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
LT-Debt-to-Total-Asset
- -

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.15

Albert Labs International LT-Debt-to-Total-Asset Calculation

Albert Labs International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0/0.164
=

Albert Labs International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0.01/0.065
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albert Labs International  (XCNQ:ABRT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Albert Labs International LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Albert Labs International's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International (XCNQ:ABRT) Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines